← boardnext 2026-09next 2028-03
AAVXF
Abivax S.A.distress 1/10 · well-funded / low risk$139.000%today0% from 52w high
Immunology / Inflammation 3
Lead: Ulcerative Colitis · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$492M
Runway
3.0 yrs
Shares 1y
0%
Price & events
+15.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+37.3%
1M
+20.2%
3M
+15.0%
6M
+1246.2%
1Y
+817.5%
2Y
+286.8%
5Y
+223.3%
All
Overview
- Market Cap
- $10.92B
- Enterprise Value
- $10.46B
- Volume
- 0
- 52 Week Range
- $7.28 – $139
- Total Shares
- 78.54M
- Float Shares
- 67.11M
- % Held by Insiders
- 4.85%
- % Held by Institutions
- 45.69%
- Beta
- -0.21
Pipeline stages · 2 programs
Obefazimod
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ABX464
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-01 | Phase 1 | Obefazimod 50 mg Capsule, Obefazimod Minitablet 50 mg | Healthy | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | Obefazimod | Moderately to Severely Active Crohn Disease | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-04-15 | Phase 2 | ABX464 | Ulcerative Colitis | — | active not recruiting |
| 2026-04 | Phase 3 | ABX464 | Ulcerative Colitis | — | active not recruiting |
| 2025-06-24 | Phase 3 | ABX464 | Ulcerative Colitis | — | completed |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-06-24 | Phase 3 | ABX464 | Ulcerative Colitis | — | completed |
Catalyst news & presentations · 1
- 2026-09-21earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 78,536,412 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Ulcerative Colitis
- LLYELI LILLY & Co$1094.4B · D3
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- PFEPFIZER INC$142.2B · D3
- TKPHFTAKEDA PHARMACEUTICAL CO LTD$53.7B · D1
- SNYSanofi$52.5B · D1
- PTGXProtagonist Therapeutics, Inc$8.6B · D0
- SYRESpyre Therapeutics, Inc.$8.5B · D6
- ANABANAPTYSBIO, INC$1.5B · D2
- ODTXOdyssey Therapeutics, Inc.$908M · D3
Recent news
- 2026-07-2317,000 Shares in Abivax SA Sponsored ADR $ABVX Bought by Militia Capital Management LLC - MarketBeat
- 2026-07-22ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
- 2026-07-21Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC - MarketBeat
- 2026-07-20Bronstein, Gewirtz & Grossman, LLC Encourages Abivax S.A. (ABVX) - The National Law Review
- 2026-07-19ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
- 2026-07-19Principal Financial Group Inc. Increases Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
- 2026-07-17Abivax reports 87,177,069 issued shares, 89,524,616 voting rights as of July 6, 2026 - Bitget
- 2026-07-17Valerio to collaborate with Abivax, outlines pipeline progress - BioWorld News
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.